[go: up one dir, main page]

MX2023011863A - Cocristales de upadacitinib. - Google Patents

Cocristales de upadacitinib.

Info

Publication number
MX2023011863A
MX2023011863A MX2023011863A MX2023011863A MX2023011863A MX 2023011863 A MX2023011863 A MX 2023011863A MX 2023011863 A MX2023011863 A MX 2023011863A MX 2023011863 A MX2023011863 A MX 2023011863A MX 2023011863 A MX2023011863 A MX 2023011863A
Authority
MX
Mexico
Prior art keywords
cocrystals
upadacitinib
compound
pyrazi
pyrrolo
Prior art date
Application number
MX2023011863A
Other languages
English (en)
Inventor
Alessandra Mattei
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2023011863A publication Critical patent/MX2023011863A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

La descripción se relaciona con cocristales de formas en estado sólido de (3S,4R)-3-etil-4-(3H-imidazo[1,2-a]pirrolo[2,3-e]-pirazi n-8-il)-N-(2,2,2-trifluoroetil)pirrolidin-1-carboxamida (Compuesto 1). Específicamente, la presente descripción se relaciona con cocristales del Compuesto 1 y un coformador adecuado, tal como un ácido benzoico sustituido.
MX2023011863A 2021-04-07 2022-04-07 Cocristales de upadacitinib. MX2023011863A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163171855P 2021-04-07 2021-04-07
PCT/US2022/071596 WO2022217257A1 (en) 2021-04-07 2022-04-07 Cocrystals of upadacitinib

Publications (1)

Publication Number Publication Date
MX2023011863A true MX2023011863A (es) 2023-12-15

Family

ID=83546642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011863A MX2023011863A (es) 2021-04-07 2022-04-07 Cocristales de upadacitinib.

Country Status (9)

Country Link
US (1) US20240043434A1 (es)
EP (1) EP4319743A4 (es)
JP (1) JP2024514820A (es)
KR (1) KR20230167057A (es)
AU (1) AU2022255047A1 (es)
BR (1) BR112023020826A2 (es)
CA (1) CA3216378A1 (es)
MX (1) MX2023011863A (es)
WO (1) WO2022217257A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452555B2 (en) * 2003-01-21 2008-11-18 S.S.C.I., Inc. Cocrystallization
WO2011068881A1 (en) * 2009-12-01 2011-06-09 Abbott Laboratories Novel tricyclic compounds
SG11201802990RA (en) * 2015-10-16 2018-05-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
CA3067658A1 (en) * 2017-06-22 2018-12-27 Center For Intelligent Research In Crystal Engineering, S.L. Crystalline forms of beta-sitosterol
US20220002306A1 (en) * 2018-09-29 2022-01-06 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib and preparation method and use thereof
WO2020115212A1 (en) * 2018-12-05 2020-06-11 Lek Pharmaceuticals D.D. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
WO2020115213A1 (en) * 2018-12-07 2020-06-11 Lek Pharmaceuticals D.D. Solvate of a selective jak1 inhibitor
WO2020177645A1 (zh) * 2019-03-01 2020-09-10 苏州科睿思制药有限公司 一种Upadacitinib的晶型及其制备方法和用途
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
WO2021005484A1 (en) * 2019-07-11 2021-01-14 Mankind Pharma Ltd. Pyrrolidine compounds, its salt and use in the preparation of upadacitinib thereof
CZ33762U1 (cs) * 2019-12-22 2020-02-18 Zentiva, K.S. Pevné formy selektivního JAK-1 inhibitoru

Also Published As

Publication number Publication date
BR112023020826A2 (pt) 2023-12-12
EP4319743A1 (en) 2024-02-14
US20240043434A1 (en) 2024-02-08
WO2022217257A1 (en) 2022-10-13
KR20230167057A (ko) 2023-12-07
AU2022255047A1 (en) 2023-10-19
CA3216378A1 (en) 2022-10-13
EP4319743A4 (en) 2025-03-12
JP2024514820A (ja) 2024-04-03

Similar Documents

Publication Publication Date Title
MX2021013812A (es) Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo[1,2-a ]pirrolo[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil) pirrolidin-1-carboxamida y formas en estado solido de la misma.
CO6311106A2 (es) Derivados novedosos del acido oleanólico con saturacion del anillo c
CR20110313A (es) Compuestos orgánicos
CR20110312A (es) Compuestos orgánicos
ECSP11010889A (es) INHIBIDORES DE cMET
CL2021002770A1 (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
AU2011288503A8 (en) 6-Cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
MX355428B (es) Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa.
CO7170182A2 (es) Derivados de 2,2-difluoropropinamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos
PH12014501503A1 (en) Purinone derivative hydrochloride
CO6551708A2 (es) Procedimiento para la preparaci´n de {4.6- diamino-2-[1-(2- fluorobencil)-1h- pirazolo[3.4-b] piridin -3-il-]pirimidin -5-il} metilcarbamato de metilo y su purificación para su uso como principio famacéutico
CL2009000148A1 (es) Acido 2-[1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido[1,2-a]pirimidin-9-il)etilamino] benzoico; proceso para preparar su enantiomero (-) puro; composicion farmaceutica que lo comprende; y su uso en la prevencion y el tratamiento de enfermedades cardiovasculares como trombosis, enfermedades respiratorias y cancer, entre otras.
AR077144A1 (es) Derivado de fenilimidazol como inhibidor de la enzima pde10a, composiciones farmaceuticas y uso de los mismos en el tratamiento de trastornos neurodegenerativos y psiquiatricos
UY29826A1 (es) Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
MX2017012568A (es) Cristal del compuesto alquinil benceno 3,5-disustituido.
ZA202401459B (en) Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
PH12020550537A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
CL2020003015A1 (es) Conversión a escala preparativa de goniautoxinas en neosaxitoxina
MX2023011863A (es) Cocristales de upadacitinib.
MX2024013581A (es) Forma cristalina de (s)-1-(piridazin-3-ilcarbamoil)-6-azaespiro[2.5]octano-6-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ilo como inhibidor de la monoacilglicerol??lipasa
CL2022002786A1 (es) Formas cristalinas de compuestos orgánicos
PE20150965A1 (es) Azaindolinas
CL2012000478A1 (es) Formas cristalinas de 4,5,6,7-tetrahidro-11-metoxi-2-[(4-metil-1-piperazinil)metil]-1h-ciclopenta[alfa]pirrolo[3,4-c]carbazol-1,3(2h)-diona; composicion farmaceutica; y uso en el tratamiento de cancer.
WO2014193881A8 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
AR082054A1 (es) Derivados aril- y heteroarilamida como inhibidor de enzima pde10a